Premium
Vitamin D Attenuates Left Atrial Volume Changes in African American Males with Obesity and Prediabetes
Author(s) -
Chacko Satish Jacob,
Pauwaa Sunil,
Barengolts Elena,
Ciubotaru Irina,
Kansal Mayank M.
Publication year - 2016
Publication title -
echocardiography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.404
H-Index - 62
eISSN - 1540-8175
pISSN - 0742-2822
DOI - 10.1111/echo.13159
Subject(s) - prediabetes , medicine , cardiology , obesity , vitamin d and neurology , endocrinology , diabetes mellitus , type 2 diabetes
Vitamin D deficiency is common among African Americans in the United States and is associated with increased cardiovascular disease risk. In this study, prediabetic African American males who were found to be vitamin D–deficient were randomized to vitamin D supplementation and assessed for changes in left atrial ( LA ) volume. Prediabetic African American males who were vitamin D–deficient (25( OH )D: 5.0–29 ng/mL) were randomized to high‐dose ergocalciferol or placebo. Echocardiography was performed at baseline and at 1 year. Ejection fraction ( EF ), septal and posterior wall thickness, LA area, LA length, LA volume, E, A, septal and lateral e' and a', deceleration time, and isovolumetric relaxation time were collected. Eighty‐one of 158 (51%) subjects received vitamin D 2 . Baseline characteristics were similar among both groups. In the placebo group, left atrial volume significantly increased on follow‐up ( LA volume increased 6.3 mL, P = 0.0025). Compared with placebo group, the treatment group with ergocalciferol had attenuated increases in left atrial volume ( LA volume increased 2.6 mL, P = 0.29). Changes in left atrial volume persisted when indexed to body surface area. There was no significant difference in other diastolic parameters and blood pressure between groups. In conclusion, vitamin D–deficient prediabetic African American males who were treated with high‐dose vitamin D 2 were found to have attenuated increases in left atrial volume compared with controls over 12‐month follow‐up.